[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628415":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":28,"responsibleParty":43,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":19,"maxAge":19,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":71,"whyStopped":19,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":57},{"fullName":5,"class":6},"University of Calgary","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Bacteriophage drug product","EXPERIMENTAL","Five phage anti-Staphylococcus aureus bacteriophage cocktail",[13],"Biological: Five phage anti-Staphylococcus aureus bacteriophage cocktail",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Five phage anti-Staphylococcus aureus bacteriophage cocktail for targeted treatment of a Staphylococcus lugdunensis infection.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"James N Powell, MD","CONTACT","403-536-3725","jamesn.powell@albertahealthservices.ca",{"name":27,"role":23,"phone":24,"phoneExt":19,"email":19},"Teresa Nguyen",[29],{"facility":30,"status":19,"city":31,"state":19,"zip":19,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Foothills Medical Centre, University of Calgary","Calgary","Canada","CA",{"type":35,"coordinates":36},"Point",[37,38],-114.08529,51.05011,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":24,"phoneExt":19,"email":25},"James Powell",{"type":44,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[46],{"name":47,"class":48},"Qeen Biotechnologies","INDUSTRY","100628415","phase-1-bacteriophage-therapy-for-staphylococcus-lugdunensis-prosthetic-joint-infection-100628415",false,"NCT07461337","Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection","Inclusion Criteria:\n\n* Diagnosis of active chronic prosthetic joint infection\n* Causative bacteria is susceptible to bacteriophage therapy in vitro\n* History of multiple failed antibiotic and surgical interventions\n\nExclusion Criteria:\n\n* Stage 5 chronic kidney disease\n* Cirrhosis\n* A known allergy to phage products\n* Fever\n* Involvement in another clinical trial\n* Pregnancy","FEMALE",{"count":57,"type":58},1,"ESTIMATED","INTERVENTIONAL",[61,62],"PHASE1","PHASE2","This is a single-patient, phase I\u002FII clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Staphylococcus lugdunensis prosthetic joint infection of the hip. The patient has exhausted all conventional therapies, both surgical and medical, at considerable detriment to their quality of life. The treatment involves 2 intra-articular injections of bacteriophages into the joint and surrounding area and 14 days of intravenous phage therapy. The goal is to eliminate the infection and prevent further complications, providing a potential new treatment avenue for patients with difficult-to-treat infections.",[65,66],"Prosthetic Joint Infections of Hip","Bacteriophage Therapy",[68,69,70],"Bacteriophage","Periprosthetic joint infection","Phage therapy","NOT_YET_RECRUITING","2026-03-04",{"date":74,"type":75},"2026-03-10","ACTUAL",{"date":77,"type":58},"2026-03",{"date":79,"type":58},"2027-03",{"name":5,"class":6}]